Case Report

Dramatic Improvement of Subcutaneous Calcinosis by Intermittent, High-Dose Etidronate plus Cimetidine in a Patient with Juvenile Dermatomyositis

Takayuki Wakabayashi,¹ Noriko Sasaki,¹ Naofumi Chinen,² and Yasuo Suzuki²

¹Department of Rheumatology, Tokai University Hachioji Hospital, 1838 Ishikawamachi, Hachioji 192-0032, Japan
²Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara 259-1193, Japan

Correspondence should be addressed to Yasuo Suzuki; y3suzuki@is.icc.u-tokai.ac.jp

Received 18 June 2015; Revised 2 November 2015; Accepted 2 November 2015

Academic Editor: Jamal Mikdashi

Copyright © 2015 Takayuki Wakabayashi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A 17-year-old boy with juvenile dermatomyositis presented with typical skin symptoms, mild myositis, and bilateral lower limb calcinosis. His skin and muscle symptoms responded to treatment with prednisolone and azathioprine. However, calcinosis did not improve, and the patient had a limited range of knee joint motion and resultant disturbance of daily activities. Cimetidine was combined with intermittent administration of high-dose etidronate, leading to marked improvement of both subcutaneous and muscular calcinosis with no skeletal adverse reactions during a long treatment period exceeding 5 years. As a result, the range of knee joint motion has increased and performance of daily activities has improved.

1. Introduction

Calcinosis occurs in various rheumatic diseases, such as systemic lupus erythematosus, scleroderma, and dermatomyositis [1]. Calcinosis is rare in adult dermatomyositis but is common in juvenile dermatomyositis, occurring in approximately 40% of patients [2]. Although various treatments have been tried for calcinosis and some have been reported to be effective, there is still no standard treatment modality. Here we report a patient with juvenile dermatomyositis in whom severe calcinosis was markedly improved by prolonged intermittent, high-dose administration of etidronate plus cimetidine.

2. Case Presentation

This patient was a 17-year-old boy who developed facial erythema and calcinosis around the left knee and femoral region at the age of 15 in 2001. He had undergone extensive resection of subcutaneous calcinosis within the year. In January 2003, he was referred to our hospital because of pain in the right knee and femoral region and skin rash on the face, the anterior chest, and the upper limbs. Physical examination revealed erythema of the forehead and buccal region, a V sign, a shawl sign, nail bed angiitis, and Gottron's papules. Although limb muscle weakness and elevation of muscle enzymes were slight, juvenile dermatomyositis was diagnosed because plain and contrast-enhanced MRI of the right femoral region revealed muscular atrophy, increased signal intensity on fat-suppression T2-weighted images, and enhancement by Gd-DTPA. There was prominent induration due to subcutaneous calcinosis around the right knee and femoral region, and the range of knee joint motion was limited.

To treat juvenile dermatomyositis, administration of prednisolone was started at a dose of 20 mg/day. Then azathioprine was added at a dose of 100 mg/day for skin ulcers that developed during prednisolone treatment. Cimetidine was also administered for his subcutaneous calcinosis. Although his erythema, skin ulcers, and muscular symptoms
Figure 1: Before intermittent, high-dose etidronate therapy. Severe calcinosis is noted in the subcutaneous tissue and muscles of both lower limbs.

Figure 2: After 5 years of intermittent, high-dose etidronate therapy. Calcinosis shows marked improvement.

**3. Discussion**

In this patient with juvenile dermatomyositis, extensive calcinosis showed marked improvement due to prolonged treatment with cimetidine and intermittent, high-dose etidronate. Electromyography and muscle biopsy were not done in this patient because he had diagnostic skin lesions and MRI findings. Instead, the diagnosis of juvenile dermatomyositis was based on the presence of weakness of proximal muscles and the elevation of myogenic enzymes in addition to typical skin symptoms and MRI findings. Although his skin and muscle symptoms responded to treatment with prednisolone and azathioprine, extensive calcinosis of the lower limbs did not show satisfactory improvement, resulting in persistence of a limited range of knee joint motion and disturbance of daily activities. Calcinosis is not rare in patients with juvenile dermatomyositis. While the pathogenesis has not been elucidated completely, it has been suggested that the onset of calcinosis is correlated with the disease duration and the length of disease activity [3, 4]. The low dose of prednisolone used in this patient may have contributed to progression of calcinosis. It has also been reported that macrophages are involved, along with cytokines such as IL-6, IL-1β, and TNFα [5]. There seems to be little likelihood of calcinosis resolving spontaneously. Because this patient had already undergone resection of calcinosis, we considered that active dermatomyositis had persisted for a long period since that operation until he attended our hospital.

Reports have been published concerning the treatment of calcinosis with colchicine, probenecid [6, 7], aluminium hydroxide [8], diltiazem [9, 10], high-dose immunoglobulin therapy [11], bisphosphonate preparations, and anti-TNFα preparations [12], but there is still no established regimen for this condition.

Bisphosphonates inhibit the activity of osteoclasts and suppress bone resorption [1, 5], and these drugs are used for the treatment of osteoporosis, Paget’s disease of bone, bone metastasis of malignant tumors, hypercalcemia, and multiple myeloma. Etidronate inhibits bone resorption when administered at low doses, while it inhibits bone mineralization as well as bone resorption at high doses. The reported efficacy of etidronate for calcinosis in rheumatic diseases varies widely. Rabens and Bethune [13] reported that etidronate was effective for calcinosis in patients with scleroderma, while Metzger et al. [14] stated that it was ineffective for calcinosis associated with scleroderma and dermatomyositis. In the present patient with juvenile dermatomyositis, etidronate was
extremely effective for calcinosis, but this might have been partly ascribable to coadministration of cimetidine which is also considered to inhibit calcinosis. There have been reports that aminobisphosphonates such as pamidronate [15, 16] and alendronate [5] are effective for calcinosis in patients with juvenile dermatomyositis, although these aminobisphosphonates have a different mechanism of action from etidronate. Prolonged treatment with high-dose etidronate is associated with a risk of osteomalacia, which is one of the important adverse reactions to this drug. Therefore, we monitored skeletal adverse reactions periodically by taking X-ray of bones and measuring vertebral and femoral bone mineral densities. However, no deleterious effect of etidronate on bones has been observed and our patient has been able to use etidronate according to an intermittent schedule for over 5 years.

In this patient with juvenile dermatomyositis, cimetidine combined with intermittent, high-dose administration of etidronate was effective for calcinosis. Thus, bisphosphonate therapy seems to be one of the useful options for calcinosis, although further studies in more patients will be needed to confirm its efficacy and safety.

Conflict of Interests

The authors declare that they have no conflict of interests regarding the publication of this paper.

References

[1] N. Boulman, G. Slobodin, M. Rozenbaum, and I. Rosner, “Calcinosis in rheumatic diseases,” Seminars in Arthritis and Rheumatism, vol. 34, no. 6, pp. 805–812, 2005.
[2] S. L. Bowyer, C. E. Blane, D. B. Sullivan, and J. T. Cassidy, “Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification,” The Journal of Pediatrics, vol. 103, no. 6, pp. 882–888, 1983.
[3] A. M. E. Sallum, F. C. M. M. Piva, O. Doria-Filho et al., “Risk factors associated with calcinosis of juvenile dermatomyositis,” Jornal de Pediatria, vol. 84, no. 1, pp. 68–74, 2008.
[4] H. Sanner, J.-T. Gran, I. Sjaastad, and B. Flato, “Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset,” Rheumatology, vol. 48, no. 12, pp. 1541–1547, 2009.
[5] M. Mukamel, G. Horev, and M. Mimouni, “New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment,” Journal of Pediatrics, vol. 138, no. 5, pp. 763–766, 2001.
[6] H. Nakamura, A. Kawakami, H. Ida, E. Ejima, T. Origuchi, and K. Eguchi, “Efficacy of probenecid for a patient with juvenile dermatomyositis complicated with calcinosis,” Journal of Rheumatology, vol. 33, no. 8, pp. 1691–1693, 2006.
[7] E. Skuterud, O. A. Sydnes, and T. K. Haavik, “Calcinosis in dermatomyositis treated with probenecid,” Scandinavian Journal of Rheumatology, vol. 10, no. 2, pp. 92–94, 1981.
[8] W.-J. Wang, W.-L. Lo, and C.-K. Wong, “Calcinosis cutis in juvenile dermatomyositis: remarkable response to aluminium hydroxide therapy,” Archives of Dermatology, vol. 124, no. 11, pp. 1721–1722, 1988.
[9] G. M. A. Palmieri, J. I. Sebes, J. A. Aelion et al., “Treatment of calcinosis with diltiazem,” Arthritis and Rheumatism, vol. 38, no. 11, pp. 1646–1654, 1995.
[10] M. B. Oliveri, R. Palermo, C. Mautalen, and O. Hübscher, “Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis,” The Journal of Rheumatology, vol. 23, no. 12, pp. 2152–2155, 1996.
[11] M.-C. Yang, J.-H. Lee, Y.-H. Yang, and B.-L. Chiang, “Improvement of juvenile dermatomyositis with calcinosis universalis after treatment with intravenous immunoglobulin,” International Journal of Rheumatic Diseases, vol. 11, no. 1, pp. 77–80, 2008.
[12] P. Riley, L. J. Mccann, S. M. Maillard, P. Woo, K. J. Murray, and C. A. Pilkington, “Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis,” Rheumatology, vol. 47, no. 6, pp. 877–880, 2008.
[13] S. F. Rabens and J. E. Bethune, “Disodium etidronate therapy for dystrophic cutaneous calcification,” Archives of Dermatology, vol. 111, no. 3, pp. 357–361, 1975.
[14] A. L. Metzger, F. R. Singer, R. Bluestone, and C. M. Pearson, “Failure of disodium etidronate in calcinosis due to dermatomyositis and scleroderma,” The New England Journal of Medicine, vol. 291, no. 24, pp. 1294–1296, 1974.
[15] S. Slimani, A. Abdessemed, A. Haddouche, and A. Ladjouze-Rezig, “Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate,” Joint Bone Spine, vol. 77, no. 1, pp. 70–72, 2010.
[16] J. Martillotti, D. Moote, and L. Zemel, “Improvement of calcinosis using pamidronate in a patient with juvenile dermatomyositis,” Pediatric Radiology, vol. 44, no. 1, pp. 115–118, 2014.